What's Happening?
The U.S. Food and Drug Administration (FDA) has approved bemotrizinol as a new active ingredient for sunscreens, the first such approval since the 1990s. Bemotrizinol is known for its ability to absorb both UVA and UVB rays, offering broad-spectrum protection.
It is more photostable than other ingredients, meaning it breaks down more slowly in sunlight. The ingredient is safe for use by adults and children as young as six months, with low absorption into the body, making it suitable for sensitive skin. This approval follows advocacy from dermatology groups and aims to provide U.S. consumers with more effective sun protection options.
Why It's Important?
The introduction of bemotrizinol into the U.S. market is a significant advancement in sun protection, addressing the need for more effective sunscreen options. This is particularly important given the high rates of skin cancer in the U.S., a largely preventable disease. Bemotrizinol's approval is expected to enhance consumer confidence in sunscreen products and align U.S. standards with those of other countries where the ingredient has been used for years. The move is also seen as a response to the need for more efficient regulatory processes for over-the-counter drugs.
What's Next?
Bemotrizinol will be available in U.S. sunscreens starting August 9, 2026, initially under the brand Parsol Shield by DSM Nutritional Products. After an 18-month exclusivity period, other manufacturers will be able to include the ingredient in their products. This development is expected to lead to a wider variety of sunscreen options for consumers, improving access to advanced sun protection and potentially reducing the incidence of skin-related health issues.
